Tislelizumab

Generic Name
Tislelizumab
Brand Names
Tevimbra, Tizveni
Drug Type
Biotech
Chemical Formula
-
CAS Number
1858168-59-8
Unique Ingredient Identifier
0KVO411B3N
Background

Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).

Indication

⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。

⑵用于治疗局部晚期或转移性尿路上皮癌。

⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。

⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。

⑸用于治疗晚期恶性实体瘤

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

First Posted Date
2021-12-16
Last Posted Date
2021-12-20
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
44
Registration Number
NCT05160727
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

First Posted Date
2021-12-09
Last Posted Date
2024-11-18
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
918
Registration Number
NCT05152147
Locations
🇦🇷

Hospital de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina

🇦🇷

Fundación Centro de Medicina Nuclear y Molecular ER, Córdoba, Argentina

🇦🇷

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

and more 310 locations

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Phase 2
Active, not recruiting
Conditions
Colorectal Cancer
Interventions
Drug: Tislelizumab
First Posted Date
2021-11-10
Last Posted Date
2024-11-28
Lead Sponsor
BeiGene
Target Recruit Count
33
Registration Number
NCT05116085
Locations
🇨🇳

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

🇨🇳

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

🇨🇳

The Affiliated Hospital of Qingdao University Branch South, Qingdao, Shandong, China

and more 5 locations

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Phase 2
Conditions
Melanoma
Interventions
Drug: sitravatinib
Drug: tislelizumab
First Posted Date
2021-11-03
Last Posted Date
2021-11-04
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
37
Registration Number
NCT05104801
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

First Posted Date
2021-10-21
Last Posted Date
2024-08-22
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
118
Registration Number
NCT05086627
Locations
🇨🇳

Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Tislelizumab in Addition to BACE in Patients With NSCLC

Phase 2
Active, not recruiting
Conditions
NSCLC
Interventions
Drug: Tislelizumab
First Posted Date
2021-09-27
Last Posted Date
2022-11-01
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Target Recruit Count
30
Registration Number
NCT05058560
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Hennan, China

Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

First Posted Date
2021-09-27
Last Posted Date
2022-11-10
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05057845
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

First Posted Date
2021-09-16
Last Posted Date
2022-10-20
Lead Sponsor
Tongji Hospital
Target Recruit Count
160
Registration Number
NCT05044871
Locations
🇨🇳

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

First Posted Date
2021-09-08
Last Posted Date
2022-09-07
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT05036798
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma

First Posted Date
2021-08-27
Last Posted Date
2021-08-27
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
30
Registration Number
NCT05024266
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University School of medicine, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy